Small Leucine-Rich Proteoglycans

A proteoglycan family (SLRPs) that is defined by a central domain which consists of a variable number of repeats of the motif LXXLxLXXNxL, where L may be LEUCINE; ISOLEUCINE; VALINE; or other hydrophobic amino acids. The N-terminal contains four conserved CYSTEINE residues and may be modified depending on function. SLRPs provide structural support to the EXTRACELLULAR MATRIX and are critical for regulating its assembly and dynamics at CELL-MATRIX JUNCTIONS.

Also Known As:

Networked: 189 relevant articles (0 outcomes, 14 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Iozzo, Renato V: 29 articles (01/2021 - 09/2002)
2.	Schaefer, Liliana: 15 articles (01/2021 - 08/2004)
3.	Brézillon, Stéphane: 9 articles (11/2021 - 11/2008)
4.	Fischer, Jens W: 9 articles (11/2021 - 09/2002)
5.	Naito, Zenya: 7 articles (12/2008 - 08/2002)
6.	Maquart, François-Xavier: 6 articles (01/2016 - 06/2004)
7.	Wegrowski, Yanusz: 6 articles (01/2016 - 06/2004)
8.	Ishiwata, Toshiyuki: 6 articles (12/2008 - 08/2002)
9.	Baghy, Kornélia: 5 articles (01/2020 - 03/2011)
10.	Birk, David E: 5 articles (01/2020 - 11/2011)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2022 - "Studies have found controversial roles of osteoglycin (OGN), a classical small leucine-rich proteoglycan found in the ECM in human malignancies; however, the significance of OGN in PC has not been determined. " 01/01/2020 - "Background and Aims: Emerging studies have determined that the small leucine-rich proteoglycan (SLRP) family can aggravate tumor progression. " 06/15/2022 - "BGN belongs to class of small leucine rich proteoglycans, which is high expression in plenty of human cancers. " 04/01/2022 - "Asporin (ASPN) is a small leucine-rich proteoglycan highly expressed in CAFs of various tumors. " 03/01/2021 - "Asporin (ASPN), a small leucine-rich proteoglycan expressed predominantly by cancer associated fibroblasts (CAFs), plays a pivotal role in tumor progression. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2003 - "These results suggest that low levels of small leucine-rich proteoglycans in breast tumors may be associated with a worse prognosis in lymph node-negative invasive breast carcinomas and warrant further study with larger patient cohorts." 04/20/2021 - "Down-regulation of the small leucine-rich proteoglycan decorin in the stroma is considered a poor prognostic factor for breast cancer progression. " 12/01/2006 - "Lumican is a member of a small leucine-rich proteoglycan family, and it is reportedly overexpressed in human breast cancer. " 08/01/2002 - "Lumican is a member of a small leucine-rich proteoglycan family and its overexpression in human breast cancer tissues is reported to influence the growth of cancer cells. " 06/01/2017 - "The aim of the present study was to investigate the inhibitory effects of the two small leucine rich proteoglycans fibromodulin (Fmod) and decorin (Dcn), overexpressed using adenovirus gene transfer, on NF-κB-activity and TGF-β1-expression in the highly metastatic 4T1 breast cancer cell line. "
3.	Atherosclerotic Plaque (Atheroma) 01/01/2023 - "Several studies have previously shown that some small leucine-rich proteoglycans (SLRPs) are associated with atherosclerotic plaque. " 12/01/2004 - "In the present study, it was investigated whether decorin, a small leucine-rich proteoglycan expressed in bone and atherosclerotic plaque, is involved in arterial calcification. " 10/08/2018 - "Decorin (DCN) is a small leucine-rich proteoglycan that induces calcification of arterial smooth muscle cell and localizes to mineral deposition in human atherosclerotic plaque. " 07/01/2017 - "The pathway - composed of structural and regulatory proteins of the extracellular matrix (ECM) such as collagen, elastin, small leucine-rich proteoglycans, metalloproteinases, cathepsins and serine proteases - is one potential way of atherosclerotic plaque destabilization. "
4.	Fibrosis (Cirrhosis) 01/01/2022 - "Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis." 10/01/2012 - "We present the first identification to our knowledge of small leucine-rich proteoglycans in normal and abnormal bladder tissue, and their differential expression in the process of bladder fibrosis, consistent with experimental findings in other anatomical sites. " 01/22/2017 - "The purpose of this study is to examine whether lumican, one of the class II small leucine-rich proteoglycans, has a protective role in cardiac remodeling and fibrosis. " 02/01/2023 - "Biglycan (BGN) is a small leucine-rich proteoglycan that participates in the production of excess extracellular matrix (ECM) and is related to fibrosis in many organs. " 04/01/2008 - "Osteoglycin, one of the matrix molecules, belongs to the small leucine-rich proteoglycan gene family and might play important roles in cell growth and differentiation and in pathological processes such as fibrosis and cancer growth. "
5.	Tendon Injuries 03/01/2014 - "The purpose of this study is to define the structural, expressional, and mechanical changes in the tendon injury response, and elucidate the roles of two class I small leucine-rich proteoglycans (SLRPs). " 01/01/2022 - "Small leucine-rich proteoglycans (SLRPs) link and interact with collagen fibrils to regulate tendon structure and biomechanics, which can provide a new and promising method in the field of tendon injury management. "

Related Drugs and Biologics

1.	Decorin
2.	Biglycan
3.	Fibromodulin
4.	Lumican
5.	Kainic Acid (Kainate)
6.	Antineoplastic Agents (Antineoplastics)
7.	Collagen
8.	Proteins (Proteins, Gene)
9.	Phosphotransferases (Kinase)
10.	tyrosine receptor (receptor, tyrosine)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)